Phase 3 Study of Vfend & Eraxis Combo Therapy for Invasive Aspergillosis
Pfizer announced results from its Phase 3 study comparing combination therapy of Vfend (voriconazole; Pfizer) and Eraxis (anidulafungin; Pfizer) to Vfend monotherapy for the treatment of invasive aspergillosis (IA).